[ANZEN]Revisions of PRECAUTIONS: Inclisiran sodium,etc.posted

Imported from official source

Announcement

Safety Classified by Officially

  • Pembrolizumab
    ​(genetical recombination)
  • Tocilizumab
    (genetical recombination)
    [Tocilizumab biosimilar1]
  • Tocilizumab
    (genetical recombination)
    [Tocilizumab biosimilar2]
  • Isopropylantipyrine/acetaminophen/
    allylisopropylacetylurea/
    anhydrous caffeine
  • Salicylamide/acetaminophen/
    anhydrous caffeine/
    chlorpheniramine maleate
  • Salicylamide/acetaminophen/
    anhydrous caffeine/
    promethazine methylenedisalicylate
  • Diprophylline/
    dihydrocodeine phosphate/
    dl-methylephedrine hydrochloride/
    diphenhydramine salicylate/
    acetaminophen/bromovalerylurea
  • Elvitegravir/cobicistat/emtricitabine/
    tenofovir alafenamide fumarate
  • Darunavir ethanolate/cobicistat/
    emtricitabine/
    tenofovir alafenamide fumarate
  • Dolutegravir sodium/
    rilpivirine hydrochloride
  • Bictegravir sodium/emtricitabine/
    tenofovir alafenamide fumarate
  • Rilpivirine hydrochloride/emtricitabine/
    tenofovir alafenamide fumarate
  • OTC drugs containing Kakkonto formulation
  • Freeze-dried Bacillus Calmette-Guérin (BCG) for intravesical use
    (Japanese strain)
  • Insulin aspart
    (genetical recombination)
    (Fiasp Injection 100U/mL)
  • Doxorubicin hydrochloride
    (liposome formulations)
  • Vonoprazan Fumarate/
    Amoxicillin Hydrate/Clarithromycin
  • Vonoprazan Fumarate/
    Amoxicillin Hydrate/Metronidazole
  • Anti-human thymocyte immunoglobulin, rabbit
  • Preparations containing omeprazole
    (guidance-mandatory drugs)
  • Preparations containing rabeprazole sodium
    (guidance-mandatory drugs)
  • Preparations containing lansoprazole
    (guidance-mandatorydrugs)
  • Sulfamethoxazole/trimethoprim
    (oral dosage form)
  • Sulfamethoxazole/trimethoprim (injection)
  • Infliximab
    (genetical recombination) and biosimilars
  • This is an extract. The publication continues at the source.

    Source: Pharmaceuticals and Medical Devices Agency (Japan) website. Licence

    Read the original at the source: https://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0014.html

    Officially imported this from Pharmaceuticals and Medical Devices Agency (Japan)’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

    This publication has changed since it was first published

    3 versions recorded. The original is kept in full — nothing is overwritten.

    1. v3 imported change on current
    2. v2 imported change on Titled: “[ANZEN]Revisions of PRECAUTIONS: Anamorelin hydrochloride,etc.posted”
    3. v1 as first published on Titled: “[ANZEN]Revisions of PRECAUTIONS: Cladribine posted”

    Provenance

    Organization
    Pharmaceuticals and Medical Devices Agency (Japan) — imported from official source
    Official source
    https://www.pmda.go.jp/rss_008.xml RSS
    Imported
    October 03, 2026 20:39
    Versions
    3 recorded
    Identity
    https://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0014....

    Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.